| Literature DB >> 28814566 |
Véronique Pierrat1,2, Laetitia Marchand-Martin3, Catherine Arnaud4, Monique Kaminski3, Matthieu Resche-Rigon5, Cécile Lebeaux3, Florence Bodeau-Livinec3,6, Andrei S Morgan3, François Goffinet3,7, Stéphane Marret8,9, Pierre-Yves Ancel3,10.
Abstract
Objectives To describe neurodevelopmental outcomes at 2 years corrected age for children born alive at 22-26, 27-31, and 32-34 weeks' gestation in 2011, and to evaluate changes since 1997.Design Population based cohort studies, EPIPAGE and EPIPAGE-2.Setting France.Participants 5567 neonates born alive in 2011 at 22-34 completed weeks' gestation, with 4199 survivors at 2 years corrected age included in follow-up. Comparison of outcomes reported for 3334 (1997) and 2418 (2011) neonates born alive in the nine regions participating in both studies.Main outcome measures Survival; cerebral palsy (2000 European consensus definition); scores below threshold on the neurodevelopmental Ages and Stages Questionnaire (ASQ; at least one of five domains below threshold) if completed between 22 and 26 months corrected age, in children without cerebral palsy, blindness, or deafness; and survival without severe or moderate neuromotor or sensory disabilities (cerebral palsy with Gross Motor Function Classification System levels 2-5, unilateral or bilateral blindness or deafness). Results are given as percentage of outcome measures with 95% confidence intervals.Results Among 5170 liveborn neonates with parental consent, survival at 2 years corrected age was 51.7% (95% confidence interval 48.6% to 54.7%) at 22-26 weeks' gestation, 93.1% (92.1% to 94.0%) at 27-31 weeks' gestation, and 98.6% (97.8% to 99.2%) at 32-34 weeks' gestation. Only one infant born at 22-23 weeks survived. Data on cerebral palsy were available for 3599 infants (81.0% of the eligible population). The overall rate of cerebral palsy at 24-26, 27-31, and 32-34 weeks' gestation was 6.9% (4.7% to 9.6%), 4.3% (3.5% to 5.2%), and 1.0% (0.5% to 1.9%), respectively. Responses to the ASQ were analysed for 2506 children (56.4% of the eligible population). The proportion of children with an ASQ result below threshold at 24-26, 27-31, and 32-34 weeks' gestation were 50.2% (44.5% to 55.8%), 40.7% (38.3% to 43.2%), and 36.2% (32.4% to 40.1%), respectively. Survival without severe or moderate neuromotor or sensory disabilities among live births increased between 1997 and 2011, from 45.5% (39.2% to 51.8%) to 62.3% (57.1% to 67.5%) at 25-26 weeks' gestation, but no change was observed at 22-24 weeks' gestation. At 32-34 weeks' gestation, there was a non-statistically significant increase in survival without severe or moderate neuromotor or sensory disabilities (P=0.61), but the proportion of survivors with cerebral palsy declined (P=0.01).Conclusions In this large cohort of preterm infants, rates of survival and survival without severe or moderate neuromotor or sensory disabilities have increased during the past two decades, but these children remain at high risk of developmental delay. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.Entities:
Mesh:
Year: 2017 PMID: 28814566 PMCID: PMC5558213 DOI: 10.1136/bmj.j3448
Source DB: PubMed Journal: BMJ ISSN: 0959-8138

Fig 1 Flowchart of study population: EPIPAGE-2 cohort at 2 years corrected age. ASQ=Ages and Stages Questionnaire. Percentages in parentheses are number of events/number of survivors at 2 years eligible for the study (n=4443). *No survivors at 22 weeks and only one survivor at 23 weeks and six days. †Of the 4199 survivors at 2 years included in follow-up, 2545 had data available for both cerebral palsy and ASQ between 22 and 26 months corrected age, cerebral palsy data only were available for 1054, ASQ data only for 92, and no data were available for 508 children
Cerebral palsy, sensory disabilities, and results for Ages and Stages Questionnaire (ASQ) at 2 years corrected age by gestational age groups. Complete case analysis
| Variables | 24-31 weeks* | 24-26 weeks* | 27-31 weeks | 32-34 weeks | P value† | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of events/No in group | % (95% CI) | No of events/No in group | % (95% CI) | No of events/No in group | % (95% CI) | No of events/No in group | % (95% CI) | ||||||
|
| 128/2714 | 4.6 (3.9 to 5.5) |
|
|
|
| 9/885 | 1.0 (0.5 to 1.9) | <0.001 | ||||
| GMFCS level: | |||||||||||||
| 5 | 8/2714 | 0.3 (0.1 to 0.6) |
|
|
|
| 0/885 | 0.0 (NA) | |||||
| 3 or 4 | 24/2714 | 0.9 (0.6 to 1.3) |
|
|
|
| 0/885 | 0.0 (NA) | |||||
| 2 | 39/2714 | 1.4 (1.0 to 1.9) |
|
|
|
| 3/885 | 0.3 (0.1 to 1.0) | |||||
| 1 | 57/2714 | 2.1 (1.6 to 2.7) |
|
|
|
| 6/885 | 0.7 (0.2 to 1.5) | |||||
|
| |||||||||||||
| Deafness: | 19/2651 | 0.7 (0.4 to 1.1) |
|
|
|
| 4/866 | 0.5 (0.1 to 1.2) | 0.28 | ||||
| Bilateral | 13/2651 | 0.5 (0.2 to 0.8) |
|
|
|
| 4/866 | 0.5 (0.1 to 1.2) | |||||
| Unilateral | 6/2651 | 0.2 (0.1 to 0.5) |
|
|
|
| 0/866 | 0.0 (NA) | |||||
|
| |||||||||||||
| Blindness: | 10/2553 | 0.4 (0.2 to 0.7) |
|
|
|
| 2/847 | 0.2 (0.0 to 0.9) | 0.51 | ||||
| Bilateral | 5/2553 | 0.2 (0.1 to 0.4) |
|
|
|
| 1/847 | 0.1 (0.0 to 0.7) | |||||
| Unilateral | 5/2553 | 0.2 (0.1 to 0.5) |
|
|
|
| 1/847 | 0.1 (0.0 to 0.7) | |||||
| Squinting‡ | 152/2533 | 5.9 (5.1 to 6.9) |
|
|
|
| 30/840 | 3.6 (2.4 to 5.1) | 0.003 | ||||
| Wearing glasses‡ | 180/2527 | 7.0 (6.1 to 8.1) |
|
|
|
| 35/842 | 4.2 (2.9 to 5.7) | <0.001 | ||||
| Neuromotor or sensory disabilities§: | |||||||||||||
| Severe | 45/2524 | 1.7 (1.3 to 2.3) |
|
|
|
| 5/834 | 0.6 (0.2 to 1.4) | <0.001 | ||||
| Moderate | 48/2524 | 1.8 (1.4 to 2.5) |
|
|
|
| 3/834 | 0.4 (0.1 to 1.0) | |||||
| None or minor disabilities | 2431/2524 | 96.4 (95.6 to 97.1) |
|
|
|
| 826/834 | 99.0 (98.1 to 99.6) | |||||
| ASQ¶: | |||||||||||||
| Median (interquartile range) total ASQ score | 1884 | 229 (199-255) |
|
|
|
| 622 | 235 (205-260) | <0.001 | ||||
| ASQ score below threshold** | 797/1884 | 42.0 (39.7 to 44.2) |
|
|
|
| 225/622 | 36.2 (32.4 to 40.1) | <0.001 | ||||
| No of domains below threshold: | |||||||||||||
| 0 | 1087/1884 | 58.0 (55.8 to 60.3) |
|
|
|
| 397/622 | 63.8 (59.9 to 67.6) | <0.001 | ||||
| 1 | 441/1884 | 23.4 (21.5 to 25.4) |
|
|
|
| 139/622 | 22.3 (19.1 to 25.8) | |||||
| 2 | 171/1884 | 8.9 (7.7 to 10.3) |
|
|
|
| 51/622 | 8.2 (6.2 to 10.6) | |||||
| 3 | 101/1884 | 5.3 (4.4 to 6.4) |
|
|
|
| 24/622 | 3.9 (2.5 to 5.7) | |||||
| 4 or 5 | 84/1884 | 4.3 (3.4 to 5.3) |
|
|
|
| 11/622 | 1.8 (0.9 to 3.1) | |||||
| By domain: | |||||||||||||
| Communication | 484/1884 | 25.3 (23.4 to 27.4) |
|
|
|
| 111/622 | 17.8 (14.9 to 21.1) | <0.001 | ||||
| Gross motor | 204/1884 | 10.6 (9.2 to 12.0) |
|
|
|
| 32/622 | 5.1 (3.5 to 7.2) | <0.001 | ||||
| Fine motor | 211/1884 | 11.2 (9.8 to 12.7) |
|
|
|
| 65/622 | 10.5 (8.2 to 13.1) | 0.75 | ||||
| Problem solving | 217/1884 | 11.5 (10.1 to 13.0) |
|
|
|
| 68/622 | 10.9 (8.6 to 13.7) | 0.69 | ||||
| Personal-social | 334/1884 | 17.4 (15.7 to 19.2) |
|
|
|
| 83/622 | 13.3 (10.8 to 16.3) | <0.001 | ||||
GMFCS=Gross Motor Function Classification System; NA=not applicable.
Denominators vary according to number of missing data for each variable. Percentages are weighted to account for differences in sampling process between gestational age groups. Data are presented by gestational age grouping: 24-26 and 27-31 (both italicised), combined 24-31, and 32-34 weeks’ gestation.
*Including one survivor born at 23 weeks and six days. Percentages are weighted to account for differences in sampling process between gestational age groups.
†Comparison between gestational age groups 24-26 weeks, 27-31 weeks, and 32-34 weeks.
‡For children without blindness.
§Severe or moderate neuromotor or sensory disability: severe=cerebral palsy GMFCS levels 3-5 and/or bilateral deafness and/or bilateral blindness; moderate=cerebral palsy GMFCS level-2 and/or unilateral deafness and/or unilateral blindness. Seven infants had associated severe or moderate cerebral palsy and sensory disabilities.
¶Infants with cerebral palsy, deafness, blindness, or severe congenital anomalies were excluded (n=131).
**For each domain, a score lower than 2 standard deviations from the mean, using established screening cut-off points (Squire 200924) was reported. If a score was below threshold in at least one domain, the global ASQ was considered below threshold.
Survival, rates of cerebral palsy, and Ages and Stages Questionnaire (ASQ) scores below threshold at 2 years corrected age among complete cases and after multiple imputation by gestational age groups
| Variables | Data analysis | % (95% CI) | |||
|---|---|---|---|---|---|
| 22-31 weeks | 22-26 weeks | 27-31 weeks | 32-34 weeks | ||
|
| |||||
| Survival at 2 years corrected age* | Complete cases | 84.3 (83.2 to 85.4) |
|
| 98.6 (97.8 to 99.2) |
| Survival without neuromotor or sensory disabilities at 2 years corrected age† | Multiple imputation | 81.2 (79.9 to 82.4) |
|
| 97.5 (96.4 to 98.5) |
|
| |||||
| Cerebral palsy | Complete cases | 4.6 (3.9 to 5.5) |
|
| 1.0 (0.5 to 1.9) |
| Multiple imputation | 4.8 (4.0 to 5.6) |
|
| 1.1 (0.4 to 1.7) | |
| ASQ score below threshold§ | Complete cases | 42.0 (39.7 to 44.2) |
|
| 36.2 (32.4 to 40.1) |
| Multiple imputation | 47.8 (45.5 to 50.2) |
|
| 42.7 (38.7 to 46.7) | |
Total percentages are weighted to account for differences in sampling process between gestational age groups. Data are presented by gestational age grouping: 22-26 and 27-31 (both italicised), combined 24-31, and 32-34 weeks’ gestation.
*No missing data for survival at 2 years.
†Severe or moderate neuromotor or sensory disability: severe=cerebral palsy GMFCS levels 3-5 and/or bilateral deafness and/or bilateral blindness; moderate=cerebral palsy GMFCS level 2 and/or unilateral deafness and/or unilateral blindness. Seven infants had associated severe or moderate cerebral palsy and sensory disabilities. For some surviving children who were lost to follow-up, the disability status was unknown, and consequently only multiple imputation analysis was possible.
‡All but one neonate born at 22-23 weeks died.
§For each domain, a score lower than 2 standard deviations from the mean, using established screening cut-off points (Squire 200924) was reported. If a score was below threshold in at least one domain, the global ASQ was considered below threshold. Infants with cerebral palsy, deafness, blindness, or severe congenital anomalies were excluded (n=131).
Outcomes for children included in the nine regions participating in EPIPAGE (1997) and EPIPAGE-2 (2011) studies by weeks’ gestational age (GA)
| Outcomes | 1997 | 2011 (EPIPAGE-1 regions) | % difference 2011 | P value | % adjusted difference 2011 | P value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of events/No in group | % (95% CI) | No of events/No in group | % (95% CI) | ||||||||
|
| |||||||||||
| Survival at 2 years corrected age (weeks’ GA)‡: | |||||||||||
| 22-31 | 1690/2123 | 79.4 (77.5 to 81.2) | 1520/1861 | 84.1 (82.4 to 85.8) | 4.8 (2.6 to 6.9) | <0.001 | 6.0 (3.5 to 8.5) | <0.001 | |||
| 22-23 | 0/46 | 0.0 (NA) | 0/76 | 0.0 (NA) | 0.0 | - | 0.0 | - | |||
| 24 | 13/42 | 32.7 (18.5 to 49.7) | 28/96 | 29.2 (20.3 to 39.3) | −3.5 (−19.2 to 12.1) | 0.66 | −0.6 (−17.0 to 15.8) | 0.94 | |||
| 25-26 | 147/277 | 53.2 (46.8 to 59.5) | 231/347 | 66.6 (61.3 to 71.5) | 13.4 (6.2 to 20.6) | <0.001 | 12.1 (4.9 to 19.2) | 0.001 | |||
| 27-31 | 1530/1758 | 86.8 (85.0 to 88.4) | 1261/1342 | 94.0 (92.6 to 95.2) | 7.2 (5.4 to 9.0) | <0.001 | 7.0 (5.3 to 8.8) | <.001 | |||
| 32-34 | 1175/1211 | 97.2 (95.6 to 98.3) | 544/557 | 97.7 (96.0 to 98.8) | 0.5 (−0.2 to 1.2) | 0.17 | 0.0 (−0.9 to 0.8) | 0.73 | |||
| Survival without neuromotor or sensory disabilities at 2 years corrected age (weeks’ GA)§: | |||||||||||
| 22-31 | 74.5 (72.5 to 76.5) | 80.5 (78.7 to 82.3) | 6.1 (3.7 to 8.5) | <0.001 | 7.2 (4.7 to 9.8) | <0.001 | |||||
| 22-23 | 0.0 (NA) | 0.0 (NA) | 0.0 | - | 0.0 | - | |||||
| 24 | 29.0 (12.3 to 45.7) | 25.8 (16.9 to 34.6) | −3.2 (−20.3 to 13.8) | 0.71 | −1.9 (−18.9 to 15.2) | 0.83 | |||||
| 25-26 | 45.5 (39.2 to 51.8) | 62.3 (57.1 to 67.5) | 16.8 (3.8 to 9.4) | <0.001 | 17.6 (10.2 to 24.9) | <0.001 | |||||
| 27-31 | 82.1 (80.2 to 84.1) | 90.3 (88.7 to 92.0) | 8.2 (6.0 to 10.4) | <0.001 | 6.4 (1.1 to 4.4) | <0.001 | |||||
| 32-34 | 95.7 (94.1 to 97.4) | 96.8 (95.2 to 98.4) | 1.1 (−0.3 to 2.2) | 0.095 | 0.4 (−1.2 to 2.1) | 0.61 | |||||
|
| |||||||||||
| Cerebral palsy (weeks’ GA): | |||||||||||
| 24-31 | 129/1415 | 9.0 (7.5 to 10.6) | 71/1280 | 5.4 (4.2 to 6.8) | −3.6 (−5.3 to −1.8) | <0.001 | −3.3 (−5.0 to −1.6) | <0.001 | |||
| 24 | 1/11 | 7.1 (0.1 to 38.8) | 4/26 | 15.4 (4.4 to 34.9) | 8.2 (−11.1 to 27.6) | 0.40 | 11.4 (−22.0 to 44.7) | 0.50 | |||
| 25-26 | 23/133 | 17.8 (11.4 to 25.9) | 15/191 | 7.9 (4.5 to 12.6) | −9.9 (−16.9 to −2.9) | 0.005 | −8.6 (−16.5 to −0.6) | 0.035 | |||
| 27-31 | 105/1271 | 8.0 (6.6 to 9.7) | 52/1063 | 4.9 (3.7 to 6.4) | −3.2 (−4.9 to −1.4) | <0.001 | −2.7 (−4.5 to −0.9) | 0.003 | |||
| 32-34 | 30/847 | 2.8 (1.5 to 4.7) | 1/416 | 0.2 (0.0 to 1.3) | −2.6 (−3.2 to −1.9) | <0.001 | −3.3 (−5.9 to −0.7) | 0.014 | |||
Percentages are weighted to account for differences in sampling process between gestational age groups.
*Risk differences were estimated with a binomial model with identity link.
†Adjusted for gestational age, sex, small for gestational age, and multiple pregnancy.
‡Complete cases analysis. No survivors at 22-23 weeks in the nine regions participating in both EPIPAGE studies.
§Results based on data using multiple imputation. Severe or moderate neuromotor or sensory disability: severe=cerebral palsy GMFCS levels 3-5 and/or bilateral deafness and/or bilateral blindness; moderate=cerebral palsy GMFCS level-2 and/or unilateral deafness and/or unilateral blindness.
Comparison of maternal characteristics and obstetric and neonatal factors between 1997 and 2011 for live births included in the nine regions participating in both EPIPAGE studies by weeks’ gestational age (GA). Complete cases analysis. Data are number of events/number in group and percentage unless stated otherwise
| Variables | 1997 | 2011 (EPIPAGE-1 regions) | P value* | ||
|---|---|---|---|---|---|
|
| |||||
| Maternal age (years): | |||||
| <25 | 770/3300 | 22.3 | 456/2416 | 16.3 | <0.001 |
| 25-34 | 2015/3300 | 61.8 | 1446/2416 | 61.0 | |
| ≥35 | 515/3300 | 15.9 | 514/2416 | 22.7 | |
| Birth outside of France | 477/2978 | 17.6 | 655/2344 | 25.4 | <0.001 |
| Parents’ socioeconomic status†: | |||||
| Professional/Intermediate | 1113/3065 | 38.3 | 968/2269 | 44.8 | <0.001 |
| Others | 1746/3065 | 54.9 | 1222/2269 | 51.8 | |
| Unknown occupation | 206/3065 | 6.8 | 79/2269 | 3.4 | |
|
| |||||
| Multiple pregnancy | 1048/3334 | 31.5 | 815/2418 | 35.7 | 0.020 |
| Antenatal steroids (weeks’ GA): | |||||
| 22-31 | 1478/2054 | 73.2 | 1464/1833 | 80.9 | <0.001 |
| 22-23 | 9/44 | 24.1 | 6/72 | 8.3 | 0.024 |
| 24 | 15/40 | 38.0 | 54/95 | 56.8 | 0.056 |
| 25-26 | 166/269 | 63.7 | 276/342 | 80.7 | <0.001 |
| 27-31 | 1288/1701 | 76.9 | 1128/1324 | 85.2 | <0.001 |
| 32-34 | 836/1179 | 69.0 | 431/543 | 79.4 | <0.001 |
| Caesarean section (weeks’ GA): | |||||
| 22-31 | 1127/2100 | 52.8 | 1043/1846 | 58.5 | <0.001 |
| 22-23 | 1/46 | 1.8 | 2/73 | 2.7 | 0.71 |
| 24 | 1/41 | 2.0 | 12/92 | 13.0 | 0.027 |
| 25-26 | 72/275 | 25.9 | 138/342 | 40.4 | <0.001 |
| 27-31 | 1053/1738 | 59.7 | 891/1339 | 66.5 | <0.001 |
| 32-34 | 714/1207 | 53.1 | 278/555 | 50.1 | 0.30 |
|
| |||||
| Male | 1789/3328 | 54.0 | 1303/2418 | 53.9 | 0.96 |
| Small for gestational age‡ | 1243/3328 | 36.7 | 799/2416 | 33.3 | 0.061 |
| Surfactant (weeks’ GA)§: | |||||
| 22-31 | 992/1967 | 49.7 | 1116/1694 | 63.9 | <0.001 |
| 22-23 | 5/6 | 83.3 | 3/4 | 75.0 | 0.75 |
| 24 | 23/27 | 82.9 | 52/53 | 98.1 | 0.013 |
| 25-26 | 181/233 | 78.2 | 319/324 | 98.5 | <0.001 |
| 27-31 | 783/1701 | 45.1 | 742/1313 | 56.5 | <0.001 |
| 32-34 | 168/1170 | 8.5 | 64/536 | 11.9 | 0.037 |
| Postnatal steroids (weeks’ GA)§: | |||||
| 22-31 | 459/1965 | 23.6 | 151/1656 | 8.2 | <0.001 |
| 22-23 | 1/6 | 16.7 | 0/4 | 0.0 | |
| 24 | 13/27 | 48.6 | 15/51 | 29.4 | 0.11 |
| 25-26 | 126/232 | 55.0 | 77/319 | 24.1 | <0.001 |
| 27-31 | 319/1700 | 18.9 | 59/1282 | 4.6 | <0.001 |
| 32-34 | 26/1169 | 1.2 | 1/531 | 0.2 | 0.025 |
| Severe neonatal morbidities (weeks’ GA)§¶: | |||||
| 22-31 | 693/1906 | 36.1 | 303/1602 | 17.5 | <0.001 |
| 22-23 | 6/6 | 100.0 | 0/2 | 0.0 | |
| 24 | 26/27 | 97.1 | 28/47 | 59.6 | <0.001 |
| 25-26 | 173/229 | 74.4 | 119/293 | 40.6 | <0.001 |
| 27-31 | 488/1644 | 29.4 | 156/1260 | 12.4 | <0.001 |
| 32-34 | 83/1123 | 5.6 | 8/515 | 1.6 | <0.001 |
Denominators vary according to number of missing data for each variable. Percentages are weighted to account for differences in sampling process between gestational age groups.
*Comparison between 1997 and 2011. †Defined as highest occupational status of mother and father, or mother only if living alone. ‡Small for gestational age was defined as birth weight less than the 10th centile for gestational age and sex based on French intrauterine “EPOPé” growth curves (Ego et al 201633). §Related to infants admitted to neonatal intensive care units. ¶Severe neonatal morbidity was defined as severe bronchopulmonary dysplasia or necrotising enterocolitis stage 2-3 or severe retinopathy of prematurity stage >3 or any of the following severe cerebral abnormalities on cranial ultrasonography: intraventricular haemorrhage grade III or IV or cystic periventricular leukomalacia (Ancel et al 20152).